Drugs / PERSERIS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03978832 | Jun 2019 → May 2020 | schizophrenia | Indivior Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-09-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Results New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) tevapharm.com ↗
New data demonstrate switching to UZEDY at four weeks after the last dose of once-monthly RBP-7000 provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified |
| 2018-07-27 | Indivior Inc. | Regulatory Indivior | FDA Approves PERSERIS™ (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults indivior.com ↗
Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved PERSERISTM, the first oncemonthly subcutaneous risperidone containing, long-acting injectable (LAI) for the treatment of schizophrenia in adults. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERSERIS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03978832 ↗ |
| Known as | RBP-7000 | “RBP-7000 (PERSERIS®) is a monthly risperidone formulation (90 or 120 mg) for the treatment of schizophrenia administered by subcutaneous abdominal injection.” PMID 38388986 ↗ Feb 2024 |
| Route | Subcutaneous | “PERSERIS is an extended-release subcutaneous (SC) injectable suspension administered monthly for the treatment of schizophrenia in adults.” NCT03978832 ↗ |